Rupert Egensperger
Overview
Explore the profile of Rupert Egensperger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
903
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quach S, Schwartz C, Aumiller M, Foglar M, Schmutzer M, Katzendobler S, et al.
J Neurooncol
. 2023 Mar;
162(1):217-223.
PMID: 36928699
Purpose: Innovative, efficient treatments are desperately needed for people with glioblastoma (GBM). Methods: Sixteen patients (median age 65.8 years) with newly diagnosed, small-sized, not safely resectable supratentorial GBM underwent interstitial...
2.
Katzendobler S, Do A, Weller J, Rejeski K, Dorostkar M, Albert N, et al.
Front Oncol
. 2023 Jan;
12:1014711.
PMID: 36605448
Background: Brain metastases (BM) represent the most frequent intracranial tumors with increasing incidence. Many primary tumors are currently treated in protocols that incorporate targeted therapies either upfront or for progressive...
3.
Weller J, Katzendobler S, Blobner J, Thiele F, Becker H, Quach S, et al.
J Neurooncol
. 2022 Sep;
160(1):149-158.
PMID: 36112301
Purpose: The role of temozolomide chemotherapy alone in isocitrate dehydrogenase (IDH)-mutant astrocytomas has not been conclusively determined. Radiotherapy might be superior to temozolomide. Recent studies have linked temozolomide with induction...
4.
Katzendobler S, Do A, Weller J, Dorostkar M, Albert N, Forbrig R, et al.
Front Neurol
. 2022 Apr;
13:822362.
PMID: 35432168
Background: An integrated diagnosis consisting of histology and molecular markers is the basis of the current WHO classification system of gliomas. In patients with suspected newly diagnosed or recurrent glioma,...
5.
Biczok A, Strubing F, Eder J, Egensperger R, Schnell O, Zausinger S, et al.
Acta Neuropathol Commun
. 2021 Jul;
9(1):119.
PMID: 34193285
Primary spinal cord astrocytomas are rare, hence few data exist about the prognostic significance of molecular markers. Here we analyze a panel of molecular alterations in association with the clinical...
6.
Weller J, Katzendobler S, Karschnia P, Lietke S, Egensperger R, Thon N, et al.
J Neurooncol
. 2021 May;
153(2):283-291.
PMID: 33932195
Introduction: The role of chemotherapy alone in newly diagnosed WHO grade 2 oligodendroglioma after biopsy, incomplete or gross total resection remains controversial. We here analyze the clinical outcome of four...
7.
Lietke S, Schmutzer M, Schwartz C, Weller J, Siller S, Aumiller M, et al.
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33917116
Interstitial photodynamic therapy (iPDT) using 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PpIX) as a cytotoxic photosensitizer could be a feasible treatment option for malignant gliomas. In a monocentric cohort of consecutive...
8.
Biczok A, Karschnia P, Vitalini R, Lenski M, Greve T, Thorsteinsdottir J, et al.
Acta Neurochir (Wien)
. 2021 Mar;
163(10):2853-2859.
PMID: 33674888
Background: Prognostic markers for meningioma recurrence are needed to guide patient management. Apart from rare hereditary syndromes, the impact of a previous unrelated tumor disease on meningioma recurrence has not...
9.
Siller S, Egensperger R, Szelenyi A, Tonn J, Zausinger S, Schichor C
Acta Neurochir (Wien)
. 2020 Jun;
162(11):2895-2903.
PMID: 32524245
Background: Intraspinal epidermoid/dermoid cysts are very rare, benign tumors arising from pathological displacement of epidermal cells into the spinal canal. Literature data about the long-term outcome after microsurgical resection with...
10.
Biczok A, Jungk C, Egensperger R, von Deimling A, Suchorska B, Tonn J, et al.
J Neurooncol
. 2019 Nov;
145(3):469-477.
PMID: 31713016
Purpose: For meningiomas, the 2016 revision of the WHO classification introduced brain invasion per se as a sufficient condition to classify as grade II. We analyzed whether meningiomas previously graded...